Literature DB >> 15670207

Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome.

Stephen S A Hull, Brian Sheridan, A Brew Atkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15670207     DOI： 10.1111/j.1365-2265.2005.02193.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  5 in total

Review 1.  PPAR-gamma in Cushing's disease.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

Authors:  Marina Gradiser; Martina Matovinovic; Milan Vrkljan
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

4.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29

Review 5.  Systemic therapy of Cushing's syndrome.

Authors:  Niels Eckstein; Bodo Haas; Moritz David Sebastian Hass; Vladlena Pfeifer
Journal:  Orphanet J Rare Dis       Date:  2014-08-05       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.